Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress

- Company Focused on Commercialization in 2008 -

FREMONT, Calif., May 15 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, today announced financial results for the first quarter ended March 31, 2008, and provided an update on recent corporate and clinical developments.

"During the first quarter of 2008, we demonstrated significant clinical and commercialization progress in each of our diagnostic programs. These programs target significant unmet clinical needs and present attractive revenue opportunities. It is an exciting time as we explore strategic business development options that are synergistic with our Quest Diagnostics' alliance," said Gail Page, President and CEO of Vermillion.

The Company plans to finalize its clinical study examining the Ovarian Tumor Triage Test, now named OVA1(TM), and submit OVA1 to the U.S. Food and Drug Administration (FDA) in the second quarter of this year. Additionally, Vermillion is working on clinical studies and building market awareness of the PAD blood test, now named VASCLIR(TM) the PAD test. Throughout the remainder of 2008, the Company will focus on commercialization efforts.

First Quarter 2008 Financial Results

As a result of the November 13, 2006 sale of its former instrument business to Bio-Rad Laboratories, the Company does not anticipate significant revenue until its diagnostic tests are commercialized. During the first quarter of 2008, products revenue of $5,000 was generated from the sale of thrombotic thrombocytopenic purpura ("TTP") test component materials to The Ohio State University Research Foundation ("OSU").

Total operating expenses decreased in the first quarter of 2008 to $4.6 million, from $5.7 million in the same period last year. The decrease was due primarily to restructuring of personnel and reduced general and administrative expenses.

The Company's net loss for the first quarter of 2008 was $4.8 million, compared to $6.0 million for the same period in 2007. Basic and diluted net loss for the first quarter of 2008 was $0.76 per share based on 6.38 million total shares outstanding, compared to a basic and diluted net loss of $1.54 per share based on 3.92 million total shares outstanding for the same period in 2007. Earnings per share calculations are on a post reverse stock split basis.

At March 31, 2008, the Company's cash, short- and long-term investments totaled $14.3 million, compared to $20.4 million at December 31, 2007. Net cash used in operating activities in the first quarter of 2008 was $5.5 million. The semi-annual payment of interest of approximately $0.6 million on the senior convertible note is due during the first and third quarters, which results in higher net cash outflows for these quarters. Vermillion continues to diligently manage expenses and cash utilization.

Recent Highlights and Accomplishments

During the first and into the second quarter of the year, Vermillion achieved numerous milestones in its three leading diagnostic programs and continued to progress in its corporate development efforts.

-- PAD Diagnostic Program

* Established a clinical steering committee to provide advice on

studies to support registration of VASCLIR with the FDA and to

further potential market adoption.

* Presented data from a study providing further confirmation that the

Company's test may aid in the diagnosis of PAD. The research, which

was presented at the American College of Cardiology 57th Annual

Scientific Session, suggests that such a test may be useful in

helping determine a patient's risk for developing PAD.

* Further bolstered Vermillion's intellectual property by advancing

the Company's license agreement with Stanford University to an

exclusive level. The license from Stanford covers the development

and commercialization of a biomarker panel used to assess the risk

of PAD.

* Hosted a roundtable teleconference focusing on Vermillion's PAD

diagnostic program and the need for improved detection of this

life- and limb-threatening condition. The teleconference featured

keynote speaker John Cooke, M.D., Ph.D., Professor of Medicine at

Stanford University, whose research forms the basis of Vermillion's


* Conducted market-development activities, including working with the

PAD Coalition and implementing an online physician survey to gather

market-based information, helping to define the Company's

commercialization strategy and broaden future clinical use of


-- Ovarian Cancer Diagnostic Program

* Continued to make progress with the clinical study evaluating OVA1

and plan to submit to the FDA in the second quarter.

* Presented data from several studies demonstrating the benefits of

the Company's ovarian cancer diagnostic test programs at the

Society of Gynecologic Oncologists' (SGO) 39th Annual Meeting on

Women's Cancer. The data suggest that use of Vermillion's tests

could help better identify women with early-stage ovarian cancer

and improve detection.

* Received the distinguished SGO Basic Science Poster Award for its

abstract, "Prospective independent validation of a marker panel for

distinguishing benign from malignant pelvic masses."

-- Hematology Diagnostic Program

* Reported findings from an OSU clinical study that indicated that a

SELDI-TOF-based TTP diagnostic test, which already has been

commercially launched as a laboratory developed test by the

institution, also could be used to help estimate the risk of TTP

relapses during clinical remission. The data -- published in the

online edition of the British Journal of Haematology -- indicate

that use of the test may provide a novel screening strategy to

identify patients who may benefit from prophylactic treatment to

help prevent relapse of this serious blood disorder.

-- Corporate Developments

* Appointed John F. Hamilton, former vice president and chief

financial officer of Depomed, Inc., to the Vermillion Board of

Directors and to serve as chairman of the Audit Committee of the


* Received issuance of U.S. Patent No. 7,341,838 for the discovery of

novel forms of brain natriuretic peptide (BNP), which could

potentially improve upon the current standard of care in diagnosing

and treating cardiovascular disease. The discovery could ultimately

lead to the development of an improved, next-generation assay that

might provide physicians with additional, valuable information to

stratify patients at risk for cardiovascular disease.

* Renewed a long-standing collaboration with Johns Hopkins University

on the development of novel biomarkers that can be applied toward

disease detection, classification and monitoring of prevalent

cancers, including ovarian, breast and prostate. Vermillion will

have access to exclusive commercial rights to the discoveries made

through the partnership.

* Vermillion's stockholders and board of directors approved a 1 for

10 reverse stock split of the Company's common stock, which became

effective at the close of trading on March 3, 2008.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

Forward Looking Statements -- This news release contains forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize PAD, ovarian cancer or hematology diagnostics products in 2008 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to discover, develop, and commercialize PAD, ovarian cancer or hematology diagnostic products based on findings from its disease association studies; (3) unproven ability of Vermillion to discover or identify new protein biomarkers and use such information to develop PAD, ovarian cancer or hematology diagnostic products; (4) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its PAD, ovarian cancer or hematology diagnostic products; (5) uncertainty of market acceptance of its PAD, ovarian cancer or hematology diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; and (6) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.

- Financial statements follow -

Vermillion, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(In Thousands)


March 31, December 31,

2008 2007 (1)


Current assets:

Cash and cash equivalents $8,283 $7,617

Short-term investments, at fair value - 8,875

Accounts receivable 51 19

Prepaid expenses and other current assets 1,481 1,064

Total current assets 9,815 17,575

Property, plant and equipment, net 1,630 1,938

Long-term investments, at fair value 6,043 3,902

Other assets 67 638

Total assets $17,555 $24,053

Liabilities and Stockholders' Deficit

Current liabilities:

Accounts payable $2,648 $2,975

Accrued liabilities 2,588 3,595

Current portion of convertible senior notes,

net of discount 2,482 2,471

Total current liabilities 7,718 9,041

Long-term debt owed to related party 10,000 10,000

Convertible senior notes, net of discount 16,242 16,196

Other liabilities 150 278

Total liabilities 34,110 35,515

Stockholders' deficit:

Common stock 6 6

Additional paid-in capital 228,067 227,895

Accumulated deficit (243,988) (239,142)

Accumulated other comprehensive loss (640) (221)

Total stockholders' deficit (16,555) (11,462)

Total liabilities and stockholders' deficit $17,555 $24,053

(1) The condensed consolidated balance sheet at December 31, 2007, has

been derived from the audited consolidated financial statements at

that date included in the Company's Annual Report on Form 10-K for the

fiscal year ended December 31, 2007.

Vermillion, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)


Three Months Ended

March 31,

2008 2007


Products $5 $-

Services 48 21

Total revenue 53 21

Cost of revenue:

Products 2 -

Services 20 15

Total cost of revenue 22 15

Gross profit 31 6

Operating expenses:

Research and development 1,875 1,990

Sales and marketing 893 477

General and administrative 1,827 3,197

Total operating expenses 4,595 5,664

Loss from operations (4,564) (5,658)

Interest and other income (expense), net (332) (383)

Loss before income taxes (4,896) (6,041)

Income tax benefit (expense) 50 (6)

Net loss $(4,846) $(6,047)

Loss per share - basic and diluted (1) $(0.76) $(1.54)

Shares used to compute basic and diluted loss

per common share (1) 6,380,188 3,923,291

(1) Adjusted for March 4, 2008, 1 for 10 reverse stock split.

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Global Stem Cells Group announced the opening of a ... of Arica and Iquique in northern Chile. The facilities are part of GSCG’s expansion efforts ... protocols and techniques in stem cell medicine to patients from around the world. , The ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... , Nov. 30, 2015 Human Longevity, Inc. ... company has acquired Cypher Genomics, Inc., a leading genome ... genomic interpretation software solutions. The San Diego ... HLI including Cypher CEO and Co-founder, Ashley Van Zeeland ... Pediatric Business.  Financial details of the deal were not ...
(Date:11/30/2015)... Germany , November 30, 2015 ... Vienna, Austria to be held December 1-4, 2015. ... in Vienna, Austria to be held ... subsidiary of Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), announced that ... Suite at the 3rd European Congress of NeuroRehabilitation (ECNR) ...
Breaking Biology Technology:
(Date:11/16/2015)... JOSE, Calif. , Nov 16, 2015 /PRNewswire/ ... developer of human interface solutions, today announced expansion ... Synaptics TouchView ™ touch controller and display ... architectural revolution of smartphones. These new TDDI products ... include TD4100 (HD resolution), TD4302 (WQHD resolution), and ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/2/2015)... 2, 2015  SRI International has been awarded a ... development services to the National Cancer Institute (NCI) PREVENT ... scientific expertise, modern testing and support facilities, and analytical ... and toxicology studies to evaluate potential cancer prevention drugs. ... PREVENT Cancer Drug Development Program is an NCI-supported pipeline ...
Breaking Biology News(10 mins):